



# Fact Sheet

## About Evalve

Evalve, Inc. is a cardiac medical device company developing leading-edge technology to enable minimally invasive repair of cardiac valves.

- **Headquarters:** Menlo Park, CA
- **Employees:** More than 100
- **Founded:** 1999

**MitraClip® system:** Designed for minimally invasive mitral valve repair. The MitraClip system received CE mark designation in 2008 and is currently available in Europe. In the U.S. it remains an investigational device and is currently in clinical trials. The catheter-based MitraClip® system is designed to clip the leaflets of the valve together to reduce mitral regurgitation. The MitraClip system incorporates three subsystems:

- Steerable Guide Catheter
- Clip Delivery System
- MitraClip device (implant)

## About Mitral Regurgitation

Mitral regurgitation is a condition that prevents the heart's mitral valve from closing completely, causing blood to flow backwards within the heart. Mitral regurgitation is the most common type of heart valve insufficiency and can ultimately lead to heart failure. Traditionally, mitral regurgitation is treated through open heart surgery to repair or replace the mitral valve.

The mitral valve is the "inflow valve" for the left side of the heart, separating the left atrium (a chamber in the heart which collects blood from the lungs) from the left ventricle (the heart's main pumping chamber).

## Market Size

- Mitral regurgitation is the most common type of heart valve insufficiency; more than 600,000 patients are diagnosed annually in the U.S. and Europe.
- Less than 20 percent of patients diagnosed annually in the U.S. and Europe are treated surgically. The remaining 80 percent are either non-surgical candidates or treated for symptomatic relief only.